Slide 1: Immunic Therapeutics Fourth Quarter and Year End 2023 Financial Results and Corporate Update
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21€ of the Securities
Slide 3: Agenda
Agenda Fourth Quarter and Year End 2023 Financial Results and Corporate Update 02 | Fourth Quarter 2023 and Subsequent Highlights 04 | Q&A Session Financial and Operating Results Summary and Highlights 03 | Anticipated Clinical Milestones 3 | © immunic, inc. | Feb/22/2024 & Immunic
Slide 4: Fourth Quarter 2023 and Subsequent Highlights
Slide 5: January 2024: Three-Tranche Private Placement of up to $240M, Cash Runway Extended
January 2024: Three-Tranche Private Placement of up to $240M, Cash Runway Extended Into Q3/2025 Based on Initial S8OM Tranche Private Investmentin Public Equity (“PIPE”) financing Total Gross Proceeds Participating Investors Closing Date Lead Placement Agent / Placement Agent / Capital Markets Advis
Slide 6: October: Reported Positive Interim Data from Phase 2 CALLIPER Trial in Progressive MS
October: Reported Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Improvements in Serum Nfl for Vidofludimus Calcium Consistent Throughout the Overall PMS Population and All Subtypes Mean Change to Week 24 as Compared to Placebo in % of Bas
Slide 7: NfL Reduction Compares Favorably with Other MS Therapies
NfL Reduction Compares Favorably with Other MS Therapies CALLIPER Interim Data Compared to Select Historical Trials Vidofludimus Ocrelizumab Vidofludimus Siponimod _Vidofludimus _Siponimod Vidofludimus Ocrelizumab — Evobrutinib PPMS PPMS n-aSPMS n-aSPMS aSPMS aSPMS RRMS RMS RRMS (CALLIPER) (ORATORIO
Slide 8: October: Presented Phase 2 EMPhASIS Trial Data of Vidofludimus Calcium in RRMS
October: Presented Phase 2 EMPhASIS Trial Data of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023 = MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting = October 11-13 in Milan, Italy = Virtual e-poster: Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple
Slide 9: November: Expanded Vidofludimus Calcium Patent Portfolio with Two New Patents
November: Expanded Vidofludimus Calcium Patent Portfolio with Two New Patents Granted in the US, Protection Currently Expected Into 2041 in the US Notice of Allowance from the USPTO for patent application 17/992,162, covering the dosing regimens associated with vidofludimus calcium and other salt as
Slide 10: October: Presented Two Abstracts at the UEG Week 2023
October: Presented Two Abstracts at the UEG (United European Gastroenterology) Week 2023 (October 14-17 in Copenhagen, Denmark) = Positive Phase 1b Data of IMU-856 in Celiac Disease Positive Phase 2 Maintenance Phase Data of Vidofludimus Calcium in UC = Moderated Poster: Franziska Burianek, M.D., =
Slide 11: November: Presented Phase 1b Data of IMU-856 in Celiac Disease
November: Presented Phase 1b Data of IMU-856 in Celiac Disease at the AOECS 35th General Assembly Conference 2023 11 | © immunic, inc. | Feb/22/2024 | ema: = Association of European Coeliac Societies (AOECS) 35th General Assembly Conference 2023 = November 2-5 in Athens, Greece = Virtual e-poster: F
Slide 12: Financial and Operating Results
Slide 13: Consolidated Statements of Operations
Consolidated Statements of Operations (In thousands, except share and per share amounts, unaudited) Years Ended December 31, 2023 2022 (Operating expenses: Research and development $83,215] $71,255] General and administrative 16,008 15,263| Goodwill impairment 4 32,970] Total operating expenses 99,2
Slide 14: Anticipated Clinical Milestones
Slide 15: Several Clinical Value Inflection Points Ahead
Several Clinical Value Inflection Points Ahead IMU-838 Readout phase 2 CALLIPER trial in PMS estimated for April 2025 Interim futility analysis phase 3 ENSURE IMU-838 program estimated for late 2024 in RMS Readout first phase 3 ENSURE trial estimated for Q2/2026 Phase 2 clinical trial in preparation
Slide 16: Q&A Session
Slide 17: Summary and Highlights
Slide 18: Advanced Clinical Pipeline
Advanced Clinical Pipeline Well Differentiated Programs in Various Phases of Clinical Development Program Preclinical Phase 1 Phase 2 Phase 3 Vidofludimus Calcium (umu-838) Ulcerative Colitis (UC) — CALDOSE-1 Tri IMU-856 IMU-381 = Completed or ongoing In preparation or planned 18 | © immunic, inc. |
Slide 19: Thank You!
Thank You! Jessica Breu Vice President Investor Relations & Communications & Phone: +49-89-2080477-09 ©& Email: ir@imux.com © Web: www.imux.com 19 | © immunic, inc. | Feb/22/2024 Immunic, Inc. 1200 Avenue of the Americas New York City, NY 10036 USA Immunic AG Lochhamer Schlag 21 82166 Grifelfing (Mu